Tanios S. Bekaii-Saab, MD

Tanios S. Bekaii-Saab, MD, describes the future direct of clinical research into immune check point inhibitors for solid tumors, which he believes will be to explore additional combinations with targeted therapies.

Tanios S. Bekaii-Saab, MD, provides insight into ongoing research exploring novel combinations of tyrosine kinase inhibitors and immune checkpoint inhibitors across solid tumors.

Liver injury can occur within 2 weeks of starting therapy with a tyrosine kinase inhibitor, although it can also be seen as late as 2 months, describes Tanios S. Bekaii-Saab, MD, making vigilance key for proper mitigation of this adverse event.

Tanios S. Bekaii-Saab, MD, describes the hepatotoxicity commonly seen with tyrosine kinase inhibitors (TKIs) and how to monitor and detect it with aspartate aminotransferase (AST) and alanine transaminase (ALT).

Tanios S. Bekaii-Saab, MD, describes the common adverse events associated with each type of tyrosine kinase inhibitor (TKI), which are specific to the targets hit by that TKI and commonly include fatigue and hepatotoxicity.

Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.

Tanios S. Bekaii-Saab, MD, discusses the safety profile of the combination of tucatinib and trastuzumab in patients with HER2-amplified metastatic colorectal cancer.